Compare ANIK & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIK | CRDF |
|---|---|---|
| Founded | 1983 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.4M | 130.7M |
| IPO Year | 1996 | 2012 |
| Metric | ANIK | CRDF |
|---|---|---|
| Price | $14.20 | $1.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $17.00 | $9.63 |
| AVG Volume (30 Days) | 129.7K | ★ 686.2K |
| Earning Date | 06-02-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.16 | 27.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $112,819,000.00 | $365,993.00 |
| Revenue This Year | $5.98 | N/A |
| Revenue Next Year | $7.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $7.90 | $1.48 |
| 52 Week High | $16.70 | $4.56 |
| Indicator | ANIK | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 71.36 | 45.54 |
| Support Level | $9.43 | $1.51 |
| Resistance Level | N/A | $2.41 |
| Average True Range (ATR) | 0.74 | 0.14 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 80.89 | 55.00 |
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.